Latest Research on Trt And Diabetes Management: 2024-2025 Update
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
The relationship between Testosterone Replacement Therapy (TRT) and diabetes management continues to be a dynamic area of research. Recent studies from 2024 and 2025 are...
# Latest Research on TRT And Diabetes Management: 2024-2025 Update
The relationship between Testosterone Replacement Therapy (TRT) and diabetes management continues to be a dynamic area of research. Recent studies from 2024 and 2025 are providing a more nuanced understanding of TRT's role in glycemic control and the prevention of type 2 diabetes (T2D). This expanded review delves deeper into the mechanisms, clinical implications, and practical considerations for integrating TRT into the management strategy for men with low testosterone and diabetes or prediabetes.
TRT and Glycemic Control: A Mixed Picture
While some studies have shown promising results, the overall picture regarding TRT and glycemic control is mixed. A 2024 study in JAMA Internal Medicine found that TRT did not significantly improve glycemic control in men with prediabetes or diabetes. This particular study, a randomized controlled trial, focused on the effect of testosterone on the progression from prediabetes to diabetes, and while it observed a reduction in diabetes incidence, the direct impact on established glycemic markers like HbA1c in the overall cohort was not statistically significant [1].
However, other research, such as a 2024 study in Diabetes, Obesity and Metabolism, suggests that TRT can reduce insulin resistance in men with metabolic syndrome [3]. This discrepancy often arises from differences in study design, patient populations (e.g., severity of hypogonadism, presence of metabolic syndrome, baseline glycemic control), and the duration of TRT. The proposed mechanisms for improved insulin sensitivity include:
Increased Lean Muscle Mass: Testosterone is anabolic, promoting muscle protein synthesis. Increased muscle mass can enhance glucose uptake and utilization, thereby improving insulin sensitivity [4].
Reduced Adiposity: TRT has been shown to reduce visceral fat, which is metabolically active and contributes to insulin resistance and inflammation [5].
Direct Pancreatic Beta-Cell Effects: Some preclinical studies suggest that testosterone may have direct protective effects on pancreatic beta-cells, although this mechanism requires further human validation [6].
Modulation of Adipokines: Testosterone can influence the secretion of adipokines like adiponectin and leptin, which play roles in insulin sensitivity and energy metabolism [7].
Clinical Implications for Glycemic Control
For clinicians, this mixed picture emphasizes the need for individualized patient assessment. TRT should not be viewed as a primary diabetes treatment, but rather as a potential adjunctive therapy for hypogonadal men with diabetes or prediabetes who may benefit from its broader metabolic effects. Monitoring of HbA1c, fasting glucose, and insulin sensitivity markers (e.g., HOMA-IR) remains crucial.
Prevention of Type 2 Diabetes
The potential for TRT to prevent the progression from prediabetes to T2D is a key area of investigation. A 2024 review in the Journal of Clinical Endocrinology & Metabolism evaluated recent randomized controlled trials on this topic. The findings suggest that while TRT may have a role in high-risk individuals, it is not a universal solution for T2D prevention [2].
The JAMA Internal Medicine study mentioned earlier [1] did observe a statistically significant reduction in the incidence of T2D among men receiving TRT compared to placebo over a 2-year period. This suggests that in men with prediabetes and low testosterone, TRT might slow or prevent the progression to overt diabetes. This effect is likely mediated by the improvements in body composition (reduced fat mass, increased lean mass) and insulin sensitivity.
Identifying High-Risk Individuals
Identifying men who are most likely to benefit from TRT for T2D prevention is paramount. These typically include:
Men with documented hypogonadism (total testosterone < 300 ng/dL or free testosterone below normal range).
Presence of prediabetes (HbA1c 5.7-6.4%, fasting glucose 100-125 mg/dL).
Metabolic syndrome (central obesity, hypertension, dyslipidemia, insulin resistance).
Obesity (BMI > 30 kg/m²).
| Research Area | Key Findings | Implication |
|---|---|---|
| Glycemic Control | Mixed results, may not improve in all patients | TRT is not a one-size-fits-all solution; individual assessment is key |
| T2D Prevention | Potential role in high-risk individuals; reduced incidence observed in some RCTs | Further research needed to identify responders and optimal treatment duration |
| Cardiovascular Safety | Reassuring data from the TRAVERSE trial | TRT is safe from a cardiovascular standpoint for appropriate patients |
| Body Composition | Consistent improvements in lean mass and reduction in fat mass | Contributes to metabolic benefits, including insulin sensitivity |
| Inflammation | Potential reduction in inflammatory markers | May indirectly improve metabolic health and reduce diabetes risk |
Cardiovascular Safety of TRT
The cardiovascular safety of TRT has been a long-standing concern, particularly in men with pre-existing cardiovascular risk factors, which are common in men with diabetes. The TRAVERSE trial, a large-scale, placebo-controlled, randomized clinical trial on this topic, has provided reassuring data. The results, published in 2023 (not 2026 as initially stated, with follow-up data potentially extending into 2026), indicate that TRT is not associated with an increased risk of major adverse cardiovascular events (MACE) such as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death, in men with hypogonadism and established cardiovascular disease or high cardiovascular risk [8].
This finding is critical for men with diabetes, who are already at a significantly higher cardiovascular risk. The TRAVERSE trial's robust methodology and large patient cohort (over 5,000 men) provide a strong evidence base for the cardiovascular safety of TRT when prescribed appropriately.
Implications for Diabetic Patients
Given the increased cardiovascular burden in diabetic patients, the reassuring safety profile from TRAVERSE allows clinicians to consider TRT for hypogonadal men with diabetes without undue concern for exacerbating cardiovascular risk, provided other contraindications are absent. Regular monitoring of cardiovascular parameters, as per standard diabetes management guidelines, should still be maintained.
Practical Protocols and Dosing Considerations
When considering TRT for hypogonadal men with diabetes or prediabetes, a structured approach is essential.
Initial Assessment
Morning total testosterone levels (two measurements, on separate days, between 7 AM and 10 AM).
Consider free testosterone if total testosterone is borderline or SHBG is abnormal.
LH and FSH to differentiate primary vs. secondary hypogonadism.
HbA1c, fasting glucose, oral glucose tolerance test (if indicated).
Assessment for metabolic syndrome components.
Complete blood count (CBC) to check hematocrit.
Prostate-specific antigen (PSA) and digital rectal exam (DRE) for prostate health.
Lipid panel, liver function tests.
Cardiovascular risk assessment.
TRT Modalities and Dosing
Various formulations of testosterone are available, each with its own pharmacokinetic profile and administration route.
| TRT Modality | Typical Dosing | Pros | Cons |
|---|---|---|---|
| Testosterone Injections | Testosterone cypionate/enanthate: 50-100 mg IM weekly or 100-200 mg IM every 2 weeks | Cost-effective, consistent levels (with weekly dosing), patient self-administration possible | Peaks and troughs (especially bi-weekly), injection site reactions, need for needles |
| Testosterone Gels/Creams | 50-100 mg daily (applied to skin) | Convenient, stable levels, non-invasive | Risk of transference, skin irritation, variable absorption |
| Testosterone Patches | 2-6 mg daily (applied to skin) | Consistent levels, non-invasive | Skin irritation, less common due to gels/creams |
| Testosterone Pellets | 150-200 mg per pellet, 6-12 pellets subcutaneously every 3-6 months | Long-acting, consistent levels, avoids daily application | Invasive procedure for insertion/removal, potential for extrusion or infection |
Target Testosterone Levels: The goal is to restore testosterone levels to the mid-normal range (e.g., 400-700 ng/dL) to alleviate symptoms of hypogonadism and potentially exert metabolic benefits, while minimizing adverse effects.
Monitoring During TRT
Testosterone Levels: Check 3-6 months after initiation, then annually. For injections, measure at mid-interval (e.g., 3.5 days after weekly injection). For gels, measure 2-4 hours after application.
Hematocrit: Check at baseline, 3-6 months, then annually. If >54%, reduce dose or temporarily discontinue.
PSA and DRE: Annually, or more frequently based on age and risk factors.
Glycemic Markers: HbA1c, fasting glucose every 3-6 months, as per diabetes management guidelines.
Lipid Panel: Annually.
Bone Mineral Density: Consider for men with long-standing hypogonadism, as testosterone improves BMD.
Safety Considerations and Contraindications
While TRT has a generally favorable safety profile in appropriately selected patients, certain conditions contraindicate its use or require careful monitoring.
Absolute Contraindications
Prostate Cancer: Active or history of prostate cancer. TRT is generally contraindicated due to concerns about stimulating cancer growth, though research on very low-risk prostate cancer is evolving [9].
Breast Cancer: Male breast cancer is rare but an absolute contraindication.
Untreated Severe Obstructive Sleep Apnea: TRT can exacerbate sleep apnea.
Severe Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH): TRT can worsen LUTS.
Hematocrit >54%: Risk of polycythemia and hyperviscosity.
Uncontrolled Congestive Heart Failure (NYHA Class III/IV): Potential for fluid retention.
Planned Pregnancy: TRT suppresses spermatogenesis and is contraindicated in men attempting to conceive.
Relative Contraindications/Precautions
Moderate LUTS due to BPH: Monitor closely.
History of Venous Thromboembolism (VTE): Some studies suggest a potential increased risk of VTE with TRT, though the data are mixed and often confounded [10].
Cardiovascular Disease: While TRAVERSE is reassuring, caution is still warranted, and shared decision-making with a cardiologist may be appropriate.
Key Takeaways
The effect of TRT on glycemic control is not uniform and may depend on individual patient characteristics, but it can improve insulin sensitivity and body composition.
TRT may have a role in preventing T2D in certain high-risk men with hypogonadism, particularly those with prediabetes and metabolic syndrome.
The cardiovascular safety of TRT has been largely established by the TRAVERSE trial, providing reassurance for its use in appropriate patients, including those with diabetes.
Comprehensive assessment, individualized dosing, and diligent monitoring are crucial for safe and effective TRT in this population.
TRT should be considered an adjunctive therapy, not a replacement for standard diabetes management strategies,
---